| Nov 20, 2025 | Aspen Neuroscience | $115.0M Series C | ARCH Venture Partners, Frazier Life Sciences, OrbiMed, Revelation Partners | Axon Ventures, Balyasny Asset Management, Cormorant Asset Management, Cindy Perettie, LifeForce Capital, Medical Excellence Capital, Prebys Ventures Fund, Section 32 |
| Sep 1, 2024 | CytoTronics | $14.0M Seed | LYFE Capital | Anzu Partners, BoxOne Ventures |
| Feb 13, 2024 | ProfoundBio | $112.0M Series B | Andrew Lam | Janus Henderson Investors, LifeSci Venture Partners, Josh Jin, Logos Capital, Medicxi, Nextech Invest, Octagon Capital, OrbiMed, Piper Heartland Healthcare Capital, RA Capital Management, Surveyor Capital, T. Rowe Price Associates |
| Aug 1, 2023 | Kyverna Therapeutics | $60.0M Series B | Bain Capital Life Sciences, Craig Gordon | Access Biotechnology, Northpond Ventures, venBio, Westlake Village BioPartners, Sean Harper, CAM Capital, Gilead Sciences, Insight Partners, jVen Capital, RTW Investments, Vida Ventures |
| Apr 20, 2023 | Noah Medical | $150.0M Series B | Prosperity7 Ventures, SoftBank Vision Fund | 1955 Capital, AME Cloud Ventures, Hillhouse Capital Group, Hongshan Capital Group (Sequoia Capital China), ShangBay Capital, Sunmed Capital, Tiger Global, Uphonest Capital |
| Nov 1, 2022 | iECURE | $65.0M Series A | Derek Yuan, Ph.D., Ray Camahort | ARCH Venture Partners, Nextech Invest, Versant Ventures, Tal Zaks |
| Jul 25, 2022 | MobiDrop | $14.8M Series A | LYFE Capital | Source Code Capital, Yunxiang Fund |
| May 1, 2022 | Aspen Neuroscience | $150.0M Series B | Google Ventures, LYFE Capital, Doug Fisher | Chloe Sladden, CRV, F-Prime Capital Partners, InterWest, Maven Ventures, NextView Ventures, OrbiMed, Otherwise Fund, Tiger Global Management, Tribe Capital, Dafina Toncheva, Y Combinator, Sam Altman, EDBI, Alexandria Venture Investments, ARCH Venture Partners, Frazier Life Sciences, LifeForce Capital, Medical Excellence Capital, Mirae Asset Capital, Newton Investment Management North America, NS Investment, Section 32 |
| Mar 1, 2022 | Medilink Therapeutics | $70.0M Series B | Qiming Venture Partners, LYFE Capital | Legend Capital, Loyal Valley Capital |
| Jan 1, 2022 | Zhenge Biotech | $100.0M Series C | Kevin Xu, Xiao-Tian Loi | Qiming Venture Partners, IDG Capital, Junxin Capital, Amit Kakar MD |
| Jan 1, 2022 | Kyverna Therapeutics | $85.0M Series B | Northpond Ventures | Access Biotechnology, venBio, Westlake Village BioPartners, Sean Harper, Argentum Capital Partners, CAM Capital, Mark Genovese, HealthCor, Hudson Bay Capital, Insight Partners, Intellia Therapeutics, jVen Capital, Niu (Chris) Liu, Fred Cohen |
| Jun 23, 2021 | Exegenesis Bio | $50.0M Series B | Hillhouse Capital Group | CPE, Lake Bleu Capital, Temasek Holdings |
| Apr 15, 2021 | Molecular Assemblies | $24.0M Series A | — | Agilent Technologies, Alexandria Venture Investments, Argonautic Ventures, Codexis, iSelect Fund |
| Feb 19, 2021 | Sciwind Biosciences | $37.0M Series B | LYFE Capital | Legend Capital |
| Feb 9, 2021 | Cleveland Diagnostics | $17.4M Series D | LYFE Capital | Eric A. Klein, MD |
| Jan 5, 2021 | Immuneering | $62.0M Series B | Andrew Phillips | BlackRock, Perceptive Advisors, Rock Springs Capital, Surveyor Capital, T. Rowe Price Associates |
| Dec 18, 2020 | ABclonal | $91.9M Series C | LYFE Capital | — |
| Dec 1, 2020 | CANbridge Pharmaceuticals | $43.0M Series E | Cathy Chen | Casdin Capital, Hudson Bay Capital, RA Capital Management, SPDB International, Summer Capital, Tigermed, Yali Capital |
| Nov 5, 2020 | Cytek Biosciences | $120.0M Series D | Hillhouse Capital, Andrew Levin | OrbiMed |
| Oct 10, 2020 | ImmuneOnco Biopharma | $25.0M Series B | Lilly Asia Ventures | LiCheng Asset |
| Aug 28, 2019 | HiFiBiO | $67.0M Series C | IDG Capital | Delian Capital, Hanne Capital, Hongshan Capital Group (Sequoia Capital China), Kite, VI Ventures |
| Feb 14, 2019 | Burning Rock Biotech | $125.6M Series C | GIC | CMB International, Hongshan Capital Group (Sequoia Capital China), Lilly Asia Ventures, T&Brothers Capital |
| May 16, 2018 | HiFiBiO | $37.5M Series B | Lynn Yang, James Zhao | Nest.Bio Ventures, Proxima Ventures, VI Ventures |
| May 14, 2018 | Ansun BioPharma | $85.0M Series A | Lilly Asia Ventures, Sinopharm Capital | 3E Bioventures Capital, Joincap Investment, Matrix Partners China, Oceanpine Capital, VI Ventures, YuanMing Capital |
